Request Deal Involvement

Adjuvant Capital, AXA IM and Novo led a $37m Series A round in LimmaTech Biologics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Gorrissen Federspiel

legal advisors

Gorrissen Federspiel

or

Principals

ADJUVANT CAPITAL

bidder

ADJUVANT CAPITAL

LIMMATECH BIOLOGICS

target

LIMMATECH BIOLOGICS

NOVO HOLDINGS A/S

bidder

NOVO HOLDINGS A/S

AXA INVESTMENT MANAGERS

bidder

AXA INVESTMENT MANAGERS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Adjuvant Capital, AXA IM and Novo led a $37m Series A round in LimmaTech Biologics.